Last updated: July 24, 2026
Dantrolene sodium is an older centrally acting skeletal muscle relaxant used for malignant hyperthermia management and chronic spasticity. Public clinical-trials activity in 2024-2026 is limited, with no broad late-stage registration programs visible in major registries. From a market-exposure standpoint, the near-term outlook is driven by hospital procurement for malignant hyperthermia and ongoing demand for spasticity. Patent and regulatory exclusivity are the primary determinants of generic substitution risk for U.S. injectables and any reformulated oral products.
What clinical trials are enrolling for dantrolene sodium in 2024–2026?
Featured snippet answer: As of 2024–2026, dantrolene sodium shows limited, non-expansionary clinical-trials footprints in major registries, with no dominant Phase 3 or pivotal Phase 2 program driving new U.S. approvals.
Are there Phase 3 or pivotal trials for malignant hyperthermia involving dantrolene sodium?
Published and registry-visible activity for malignant hyperthermia is typically event-driven and not designed around large, randomized efficacy endpoints. Where trials exist, they more often focus on administration workflows, peri-anesthesia logistics, or real-world utilization rather than establishing new efficacy for regulatory purposes.
Are there spasticity trials testing dantrolene sodium in combination regimens?
Spasticity studies using dantrolene have historically been small and older. Current trial activity tends to be either observational or focused on dosing tolerability and comparative muscle-relaxant positioning, rather than new drug development intended for U.S. label expansion.
Which trial registries should be tracked for dantrolene sodium updates?
For operational monitoring, the key sources are:
- ClinicalTrials.gov (U.S. study listings)
- EU Clinical Trials Register (EudraCT-linked postings)
- WHO ICTRP aggregation where available
Which companies are developing or running dantrolene sodium trials?
Featured snippet answer: Dantrolene sodium development is not characterized by large, sponsor-led late-stage programs. Trial activity, when present, is commonly conducted under investigator-initiated or hospital-network studies rather than industry-led platform development.
What sponsor patterns show up in dantrolene sodium studies?
Typical patterns for older generics and off-patent compounds include:
- academic neurology or anesthesiology sites for spasticity or malignant hyperthermia protocols
- hospital networks with perioperative registries
- protocol amendments tied to drug supply continuity rather than new chemical entities
How big is the dantrolene sodium market by use-case (malignant hyperthermia vs spasticity)?
Featured snippet answer: The highest-value and highest-assurance demand driver is hospital preparedness for malignant hyperthermia. Chronic spasticity use contributes steady volume but is less concentrated than perioperative emergency supply.
Malignant hyperthermia preparedness: why procurement drives revenue
- Dantrolene sodium is a critical emergency medicine. Hospitals standardize stockholding, which supports recurring purchasing even when outpatient spasticity use fluctuates.
- Because malignant hyperthermia is rare but high-acuity, demand is not linear with prevalence. Procurement is driven by compliance, anesthesia case volume, and institutional risk mitigation.
Chronic spasticity: what drives ongoing usage
- Demand is anchored to patient volumes with spasticity indications that historically used dantrolene.
- Shifting standard-of-care toward other antispasticity agents can cap growth but does not eliminate ongoing usage.
What is the market size projection for dantrolene sodium through 2030?
Featured snippet answer: Projection depends more on generic price erosion and supply continuity than on trial-driven label expansion. With limited visible late-stage development, baseline growth is more likely to be inflation-adjusted and volume-stable rather than innovation-led.
Scenario framework for revenue CAGR (directional)
Given the drug’s older status and typical generic dynamics:
- Base case: low single-digit growth through 2030 driven by hospital procurement cycles and inflation, offset by generic competition
- Downside: faster price compression due to additional generic entrants or supply disruptions that normalize late
- Upside: sustained hospital preparedness spending and stable conversion to injectable supply as formularies refresh
What patents protect dantrolene sodium in the US, and when do they expire?
Featured snippet answer: Dantrolene sodium is an older active, and its U.S. protection, where any remains, is generally associated with specific formulations, manufacturing processes, or labeling-related exclusivities rather than broad composition-of-matter coverage.
How to interpret patent estate risk for an older active
For legacy actives like dantrolene sodium, the practical IP question is whether any current Orange Book-listed patents cover:
- dosage form (injectable vs oral)
- formulation (excipients, particle size, stabilization)
- manufacturing method
- method of use tied to an approved indication
Where composition-of-matter is long expired, remaining exclusivity is usually narrower and easier for generics to design around.
Patent landscape mechanics that matter for generic launch
- Generics seek approval for the same dosage form and strength, then evaluate each listed patent’s claims for infringement or design-around options.
- Even with expired composition-of-matter, a formulation patent can delay an injectable launch if the generic cannot show non-infringement.
What is the Orange Book status of dantrolene sodium (injectable and oral products)?
Featured snippet answer: The Orange Book listing status for dantrolene sodium depends on the specific NDA and product code (injectable vs other dosage forms). For an older active, most entries are typically off exclusivity, with residual listings tied to formulation or manufacturing.
How Orange Book listings typically impact market entry
- Active patents listed for an NDA can force Paragraph IV litigation to carve out timelines.
- If no active patents remain, generics can file and launch without Paragraph IV delay.
When does dantrolene sodium lose exclusivity for each dosage form?
Featured snippet answer: Exclusivity loss is determined per NDA/dosage form product. For older actives, the practical answer is that exclusivity is largely concluded, and residual barriers are driven by any remaining formulation/manufacturing patents and Orange Book listings.
What timeline inputs drive the practical launch clock
- patent expiration dates for each listed patent
- any statutory exclusivities tied to specific approvals
- any existing patent litigation stay durations that push launch beyond expiry
Which generic companies are at risk for dantrolene sodium Paragraph IV challenges?
Featured snippet answer: In an off-patent legacy active, Paragraph IV risk typically clusters around any remaining Orange Book-listed patents for specific product codes (especially injectables).
What usually triggers Paragraph IV filings
- generic applicants file an ANDA for the same dosage form
- they evaluate remaining patents for each NDA product code
- they decide between:
- Paragraph IV certification (non-infringement or invalidity)
- settlement-led early entry with payment terms (if asserted patents are credible)
What patent litigation affects dantrolene sodium generics?
Featured snippet answer: Dantrolene sodium litigation is expected to be sporadic given its age, with any material disputes most likely tied to injectables or specific formulation patents listed in the Orange Book.
Litigation topics that typically appear
- infringement vs non-infringement of formulation claims
- validity arguments on novelty or obviousness
- settlement scope defining launch dates and design constraints
How does dantrolene sodium compare with alternative antispasticity drugs from a market-risk perspective?
Featured snippet answer: Market share pressure for chronic spasticity comes from broader antispasticity options. Dantrolene’s differentiator is its historical role and its established place in emergency malignant hyperthermia preparedness.
Competitive pressure map
- Chronic spasticity alternatives compete for outpatient and long-term use.
- In malignant hyperthermia, the competitive set is constrained by emergency preparedness protocols and formulary stocking.
What formulations are protected (injectable vs oral), and what generic entry barriers exist?
Featured snippet answer: Barriers, when they exist, usually sit in injectable formulation stabilization and manufacturing method claims rather than active ingredient composition.
Injectable generic risks
Common barrier types for injectables:
- stabilization and storage performance claims
- specific excipient systems affecting solubility or shelf-life
- manufacturing steps tied to impurity profiles
Oral product risks
If oral products exist in specific NDA categories:
- excipient and dissolution-rate formulation claims can matter
- process claims can matter if manufacturing routes are tightly defined
What regulatory status matters for dantrolene sodium in the US (FDA pathways, labeling, and manufacturing)?
Featured snippet answer: Dantrolene sodium products are typically accessed via ANDA pathways for generics where approved. Regulatory risk comes mainly from manufacturing controls, facility compliance, and any post-approval labeling modifications rather than from new clinical evidence.
How ANDA approvals translate to market availability
- ANDA approvals and supplements can increase supply and compress prices.
- If manufacturing-quality events occur, availability can temporarily tighten, lifting prices before normalization.
What is the commercial outlook for dantrolene sodium manufacturers in 2026–2030?
Featured snippet answer: Commercial performance is likely to track procurement cycles, generic price competition intensity, and supply stability. Without new pivotal clinical programs, product strategy tends to focus on:
- maintaining injectable supply continuity
- managing contract pricing with hospital systems
- defending any residual formulation or manufacturing IP
Key Takeaways
- Clinical development for dantrolene sodium in 2024–2026 appears limited, with no visible dominant late-stage program driving label expansion.
- Market demand is primarily hospital preparedness for malignant hyperthermia plus steady spasticity usage; growth is likely inflation and volume-stable rather than innovation-led.
- Patent and exclusivity risk is concentrated in any remaining Orange Book-listed formulation or manufacturing patents tied to specific NDA product codes, especially injectables.
- Generic entry timing in the US is determined by Orange Book listings, any Paragraph IV litigation tied to them, and settlement-driven launch dates if asserted.
FAQs
1) Are there any new FDA approvals or label expansions expected for dantrolene sodium?
No clear path of visible late-stage development has emerged that would typically produce new FDA label expansion for dantrolene sodium during 2024–2026.
2) Is dantrolene sodium demand seasonal?
Demand is more closely tied to hospital anesthesia schedules and preparedness procurement cycles than to seasonal drivers.
3) What is the biggest operational risk for dantrolene sodium supply in the US?
Manufacturing quality, contract concentration with distributors/hospitals, and facility capacity constraints for injectables.
4) Does dantrolene sodium face biosimilar competition risk?
No. Dantrolene sodium is a small-molecule drug, so biosimilar frameworks do not apply.
5) What dosing form is most likely to attract the last remaining IP barriers?
Injectables, because formulation stabilization and manufacturing method claims are more likely to persist as enforceable Orange Book listings for older actives.
References
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA (accessed 2026-07-24).
- ClinicalTrials.gov. Dantrolene sodium (search results and study listings; accessed 2026-07-24).
